Proposição de metodologia para estudo de uridina 5'-trifosfato trissódica e citidina 5'-monosfato dissódica e derivados em matriz biológica durante neuropatias periféricas

Pyrimidines uridine 5'-triphosphate trisodium (UTPt) and cytidine 5'-monophosphate disodium (CMPd) are standard nucleosides which make up nucleic acids. Efficacy and safety from UTPt and CMPd based drugs on peripheral neuropathies has already been studied. However, information regarding pharmacokinetics of UTPt and CMPd based drugs during pathological condition remains unknown. The aim of this study was to propose methodologies to quantify UTPt and CMPd in biological matrices, based on a systematic literature review. Concerning that the bioavailability of pyrimidines during peripheral neuropathies is different of observed in healthy volunteers, the available data regarding plasmatic levels of UTPt and CMPd should not be used to estimate the dose of UTPt and CMPd based drugs. Furthermore, to differentiate endogenous and exogenous pyrimidines in biological matrices the exogenous pyrimidines must be labeled with [3H] or [14C] before administration. Next, high-performance liquid chromatography (HPLC) has been the most applied technique for identification and quantitation of radiolabeled pyrimidines. We concluded that UTPt and CMPd radiolabelling, followed by chromatographic separation and detection by UV and liquid scintigraphy, is a feasible methodology for detection and quantitation of UTPt and CMPd derivatives in biological matrices.